UroGen Pharma Ltd.
URGN
$29.80
-$1.53-4.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 151.60% | 54.03% | 9.04% | 10.83% | 7.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 151.60% | 54.03% | 9.04% | 10.83% | 7.84% |
| Cost of Revenue | 77.64% | 33.10% | 33.63% | 59.26% | 34.84% |
| Gross Profit | 161.21% | 56.37% | 6.39% | 5.33% | 5.11% |
| SG&A Expenses | 47.24% | -43.56% | 29.86% | 43.73% | 28.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.58% | -45.47% | 28.35% | 37.70% | 28.41% |
| Operating Income | 45.11% | 65.44% | -56.09% | -60.41% | -43.41% |
| Income Before Tax | 34.76% | 23.59% | -45.88% | -46.64% | -34.81% |
| Income Tax Expenses | -1,317.35% | -110.38% | -1,258.24% | 2,571.05% | 625.93% |
| Earnings from Continuing Operations | 46.23% | 29.72% | -40.87% | -49.51% | -35.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.23% | 29.72% | -40.87% | -49.51% | -35.80% |
| EBIT | 45.11% | 65.44% | -56.09% | -60.41% | -43.41% |
| EBITDA | 45.20% | 65.50% | -51.08% | -60.53% | -43.82% |
| EPS Basic | 49.18% | 32.86% | -37.11% | -26.85% | -6.12% |
| Normalized Basic EPS | 38.36% | 63.50% | -41.99% | -24.39% | -5.35% |
| EPS Diluted | 49.18% | 32.86% | -37.11% | -26.85% | -6.12% |
| Normalized Diluted EPS | 38.36% | 63.50% | -41.99% | -24.39% | -5.35% |
| Average Basic Shares Outstanding | 5.82% | 4.68% | 2.73% | 17.87% | 27.96% |
| Average Diluted Shares Outstanding | 5.82% | 4.68% | 2.73% | 17.87% | 27.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |